bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
- None.
- None.
Insights
bioAffinity Technologies' recent securities purchase agreement with institutional investors is a significant event that warrants close examination. The issuance of 1,600,000 shares at a price of $1.5625 per share, along with an equal number of common warrants with an exercise price of $1.64, represents a strategic capital raise for the company. This transaction will infuse the company with immediate capital, which can be pivotal for its operational and developmental goals.
From a financial perspective, the terms of the warrants are particularly noteworthy. They are exercisable contingent upon shareholder approval, which introduces an element of uncertainty regarding the timing and potential dilution effects. The five-year expiration term of these warrants provides a long-term potential for additional capital but also implies a sustained period of potential dilution risk. Investors and analysts must factor in these aspects when assessing the company's financial health and future prospects.
Moreover, the pricing of the stock and warrants could reflect current market sentiment towards the company's valuation. A comparison with industry norms for similar transactions could provide deeper insights into investor confidence and the perceived risk/reward profile of bioAffinity Technologies.
The entry of institutional investors in bioAffinity Technologies' capital structure is a move that could signal to the market a level of institutional confidence in the company's future. Institutional investment often brings a perception of credibility and stability, which can positively influence the stock's market performance. Additionally, the capital raised through this offering is likely earmarked for specific projects or for accelerating research and development, which could have material implications for the company's growth trajectory.
Understanding the strategic intent behind the capital raise is crucial. If the funds are directed towards advancing key technologies or expanding market reach, the long-term growth prospects could be significantly enhanced. The market will be watching closely for announcements on how the raised capital will be deployed and any subsequent impact on the company's product pipeline and revenue potential.
The biotechnology sector is highly capital-intensive, with significant funds required for R&D, clinical trials and scaling up operations. For bioAffinity Technologies, raising capital through a direct offering and concurrent private placement of warrants indicates an aggressive approach to funding their initiatives. The specifics of the offering, such as the price per share and the exercise price of the warrants, are critical for assessing the company's current valuation and the investors' expectations of future growth.
It is essential to contextualize this move within the biotech industry's standards, where such capital raises are common but still carry substantial risk due to the uncertainty inherent in biotech product development. The impact of this financial move on the company's cash runway, research outcomes and any strategic partnerships will be of particular interest to stakeholders who understand the intricacies of biotech financing and development cycles.
The closing of the offering is expected to occur on or about March 8, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately
WallachBeth Capital is acting as sole placement agent for the Offering.
The common stock will be issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275608) previously filed with the
The private placement of the common warrants will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CyPath® Lung
CyPath® Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of securities and the expected closing of the offering. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading “Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed by the Company and other reports filed with the SEC from time to time. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306247837/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.
FAQ
What is the ticker symbol for bioAffinity Technologies, Inc.?
How many shares of common stock are being sold in the offering?
What is the purchase price per common share?
What is the exercise price for the common warrants?
When will the common warrants expire?
